108 related articles for article (PubMed ID: 17391490)
1. In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia.
Beesley AH; Palmer ML; Ford J; Weller RE; Cummings AJ; Freitas JR; Firth MJ; Perera KU; de Klerk NH; Kees UR
Br J Haematol; 2007 Apr; 137(2):109-16. PubMed ID: 17391490
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine.
Parker WB; Shaddix SC; Gilbert KS; Shepherd RV; Waud WR
Cancer Chemother Pharmacol; 2009 Jul; 64(2):253-61. PubMed ID: 19002461
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
Kaspers GJ; Wijnands JJ; Hartmann R; Huismans L; Loonen AH; Stackelberg A; Henze G; Pieters R; Hählen K; Van Wering ER; Veerman AJ
Eur J Cancer; 2005 Jun; 41(9):1300-3. PubMed ID: 15869873
[TBL] [Abstract][Full Text] [Related]
4. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
Larson RA
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
[TBL] [Abstract][Full Text] [Related]
5. Clofarabine and nelarabine: two new purine nucleoside analogs.
Gandhi V; Plunkett W
Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
[TBL] [Abstract][Full Text] [Related]
6. Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.
Beesley AH; Palmer ML; Ford J; Weller RE; Cummings AJ; Freitas JR; Firth MJ; Perera KU; de Klerk NH; Kees UR
Br J Cancer; 2006 Dec; 95(11):1537-44. PubMed ID: 17117183
[TBL] [Abstract][Full Text] [Related]
7. Flavopiridol displays preclinical activity in acute lymphoblastic leukemia.
Jackman KM; Frye CB; Hunger SP
Pediatr Blood Cancer; 2008 Apr; 50(4):772-8. PubMed ID: 18000861
[TBL] [Abstract][Full Text] [Related]
8. Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes.
Rapoport AP; Simons-Evelyn M; Chen T; Sidell R; Luhowskyj S; Rosell K; Obrig T; Hicks D; Hinkle PM; Nahm M; Insel RA; Abboud CN
Blood Cells Mol Dis; 2001; 27(3):610-24. PubMed ID: 11482875
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine (2-chloro-2'-fluoro-2'-deoxyarabinosyladenine)--biochemical aspects of anticancer activity.
Majda K; Lubecka K; Kaufman-Szymczyk A; Fabianowska-Majewska K
Acta Pol Pharm; 2011; 68(4):459-66. PubMed ID: 21796927
[TBL] [Abstract][Full Text] [Related]
10. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
Karp JE; Ross DD; Yang W; Tidwell ML; Wei Y; Greer J; Mann DL; Nakanishi T; Wright JJ; Colevas AD
Clin Cancer Res; 2003 Jan; 9(1):307-15. PubMed ID: 12538483
[TBL] [Abstract][Full Text] [Related]
11. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
12. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.
Lotfi K; Månsson E; Spasokoukotskaja T; Pettersson B; Liliemark J; Peterson C; Eriksson S; Albertioni F
Clin Cancer Res; 1999 Sep; 5(9):2438-44. PubMed ID: 10499616
[TBL] [Abstract][Full Text] [Related]
13. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
Gandhi V; Kantarjian H; Faderl S; Bonate P; Du M; Ayres M; Rios MB; Keating MJ; Plunkett W
Clin Cancer Res; 2003 Dec; 9(17):6335-42. PubMed ID: 14695132
[TBL] [Abstract][Full Text] [Related]
15. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
Estlin EJ; Yule SM; Lowis SP
Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927
[TBL] [Abstract][Full Text] [Related]
16. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study.
Lu A; Fang Y; Du X; Li Y; Cai Z; Yu K; Zhao L; Wang B; Wu J; Cheng Y; Zuo Y; Jia Y; Tan F; Ding L; Lu J; Zhang L; Huang X
Blood Cancer J; 2016 Feb; 6(2):e400. PubMed ID: 26918364
[No Abstract] [Full Text] [Related]
18. Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro.
Bieber MM; Twist CJ; Bhat NM; Teng NN
Pediatr Blood Cancer; 2007 Apr; 48(4):380-6. PubMed ID: 16421902
[TBL] [Abstract][Full Text] [Related]
19. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
DeAngelo DJ
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
[TBL] [Abstract][Full Text] [Related]
20. Cellular drug sensitivity of immunophenotypic subgroups of childhood acute lymphoblastic leukemia.
Pieters R; Kaspers GJ; van Wering ER; Huismans DR; Loonen AH; Hählen K; Veerman AJ
Recent Results Cancer Res; 1993; 131():249-56. PubMed ID: 8210644
[No Abstract] [Full Text] [Related]
[Next] [New Search]
